Liraglutide vs Semaglutide
Side-by-side from the data we track independently: what each compound is, how it's typically dosed, what the community reports, and what it actually costs from live vendor offers. Full evidence lives on each peptide's page.
| Liraglutide | Semaglutide | |
|---|---|---|
| What it is | First-generation GLP-1 receptor agonist by Novo Nordisk. FDA-approved as Victoza (type 2 diabetes) and Saxenda (weight loss). Daily subcutaneous injection with well-established safety profile. | GLP-1 receptor agonist used for weight management and type 2 diabetes. Originally developed by Novo Nordisk. |
| Category | weight_loss | weight_loss |
| Typical dose | — | — |
| Half-life | ~13h | ~168h |
| Community reports | 177 firsthand reports (79.7% positive). Most reported: Weight loss & appetite control (155), Blood sugar control & Type 2 Diabetes (22). | 732 firsthand reports (85.8% positive). Most reported: Weight management & obesity (609), Other metabolic health benefits (72), Type 2 diabetes control (51). |
| Live pricing | From $3.14/mg across 7 vendors. Compare prices → | From $0.46/mg across 158 vendors. Compare prices → |
Common questions
Which is cheaper per mg, Liraglutide or Semaglutide?
On live captured offers, Semaglutide is currently cheaper per mg: from $0.46/mg across 158 vendors, versus Liraglutide from $3.14/mg across 7 vendors (USD-converted; prices change between sweeps).
Community counts reflect substantiated, linkable reports only. Prices are captured from vendor catalogues and change between sweeps. Research use only — nothing here is medical advice.